Literature DB >> 12685513

Randomized, comparative, double-blind study of amlodipine vs. nicardipine as a treatment of isolated systolic hypertension in the elderly.

Claire Mounier-Véhier1, Olivier Jaboureck, Jean-Paul Emeriau, Corine Bernaud, Pierre Clerson, Alain Carre.   

Abstract

A 90-day, multicenter, randomized, double-blind, parallel-group study was conducted to compare the efficacy of amlodipine (once a day) with nicardipine (two to three times a day), in the treatment of isolated systolic hypertension (ISH) in the elderly. Patients (n = 133) aged > or = 60 years, with ISH were randomized to receive either amlodipine 5 mg/day, or nicardipine 60 mg/day (titrated if necessary to 10 mg/day and 100 mg/day, respectively) for 90 days. Efficacy was assessed by measuring office blood pressure (BP), and 24-h ambulatory blood pressure monitoring (ABPM). The two treatments substantially and comparably reduced office systolic blood pressure (SBP) and pulse pressure (PP), and also produced a slight decrease in diastolic blood pressure (DBP). Amlodipine reduced SBP, as assessed by ABPM, to a significantly greater extent than nicardipine. Both treatments were well-tolerated. The sustained effect of amlodipine, compared with nicardipine, was reflected in its significantly greater antihypertensive activity, particularly during the nocturnal period, as assessed by ABPM. The study demonstrates that once a day dose of amlodipine is an effective antihypertensive treatment for elderly ISH patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12685513     DOI: 10.1046/j.1472-8206.2002.00129.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  2 in total

1.  Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study.

Authors:  Antonio Coca Payeras; Krzysztof Sladek; Giuseppe Lembo; Marco Alberici
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

2.  Rationale, study design, and implementation of the ACS1 study: effect of azilsartan on circadian and sleep blood pressure as compared with amlodipine.

Authors:  Kazuomi Kario; Satoshi Hoshide
Journal:  Blood Press Monit       Date:  2014-06       Impact factor: 1.444

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.